(NASDAQ: CORT) Corcept Therapeutics's forecast annual revenue growth rate of 13.42% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.22%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.95%.
Corcept Therapeutics's revenue in 2024 is $523,529,000.On average, 4 Wall Street analysts forecast CORT's revenue for 2024 to be $65,854,747,807, with the lowest CORT revenue forecast at $64,611,961,813, and the highest CORT revenue forecast at $67,207,476,167. On average, 4 Wall Street analysts forecast CORT's revenue for 2025 to be $67,225,695,782, with the lowest CORT revenue forecast at $57,920,677,917, and the highest CORT revenue forecast at $73,711,358,304.
In 2026, CORT is forecast to generate $82,448,028,281 in revenue, with the lowest revenue forecast at $81,824,813,322 and the highest revenue forecast at $83,352,137,653.